The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.

dx.doi.org/10.1016/j.eururo.2020.10.016, hdl.handle.net/1765/131691
European Urology : Official Journal of the European Association of Urology
Erasmus MC: University Medical Center Rotterdam

de Wit, R, Tombal, B, & Freedland, S. (Stephen). (2020). Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer. European Urology : Official Journal of the European Association of Urology. doi:10.1016/j.eururo.2020.10.016